Results 231 to 240 of about 118,210 (303)

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen   +6 more
wiley   +1 more source

Regional Variation in Reimbursement for Body Contouring Surgery: A Claims-based Analysis across the United States. [PDF]

open access: yesPlast Reconstr Surg Glob Open
Colon-Sanchez C   +4 more
europepmc   +1 more source

Sensor‐Detected Hypoglycaemia Is Associated With Inflammatory Protein and Immune Cell Alterations in People With Diabetes: Findings From the Hypo‐METRICS Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Experimental hypoglycaemia induces a persistent inflammatory response. We investigated whether real‐life sensor‐detected hypoglycaemia (SDH) is associated with immune parameters in people with Type 1 and Type 2 diabetes and explored potential differences between the groups.
Mandala Ajie   +15 more
wiley   +1 more source

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aim Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with FD. Methods We conducted
Leandra Serio   +8 more
wiley   +1 more source

From hepatic to hematopoietic: LRH‐1's expanding cellular repertoire to the immune system

open access: yesThe FEBS Journal, EarlyView.
The nuclear receptor LRH‐1 is a well‐characterized regulator of endodermal tissue. Yet, increasing evidence indicates that LRH‐1, although expressed at low levels, is also a critical regulator of the hematopoietic system. LRH‐1 regulates the immune system by contributing to immune cell‐specific functions.
Lukas Meisinger   +3 more
wiley   +1 more source

Human APOBEC3G suppresses homologous recombination and LIG4‐independent end joining in DNA double‐strand break repair

open access: yesThe FEBS Journal, EarlyView.
Chromosomal DNA double‐strand breaks (DSBs) are repaired by homologous recombination and nonhomologous end joining (NHEJ). Recent work has additionally established theta‐mediated end‐joining (TMEJ) as a mechanism for DSB joining. Cells lacking NHEJ and TMEJ can repair DSBs in a homology‐dependent manner.
Shinta Saito   +6 more
wiley   +1 more source

National Medicare trends in navigation-assisted spine surgery: A temporal and geographic analysis. [PDF]

open access: yesJ Craniovertebr Junction Spine
Sanghera BS   +8 more
europepmc   +1 more source

The trimeric Shu complex in C. elegans is an ATPase that remodels RAD51 filaments in the homologous recombination‐associated DNA damage response

open access: yesThe FEBS Journal, EarlyView.
The C. elegans Shu complex (RFS‐1/RIP‐1/SWS‐1) is a DNA‐dependent ATPase that regulates RAD‐51 filaments during homologous recombination. The trimer preferentially binds 5′‐exposed DNA, remodels RAD‐51 filaments via ATP hydrolysis, and stabilizes filaments through ATP binding.
Sam Siu Hang Chu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy